MA50582A - Méthodes de traitement et de protection contre une maladie cardiaque, une maladie cardiovasculaire et des états et des symptômes associés - Google Patents

Méthodes de traitement et de protection contre une maladie cardiaque, une maladie cardiovasculaire et des états et des symptômes associés

Info

Publication number
MA50582A
MA50582A MA050582A MA50582A MA50582A MA 50582 A MA50582 A MA 50582A MA 050582 A MA050582 A MA 050582A MA 50582 A MA50582 A MA 50582A MA 50582 A MA50582 A MA 50582A
Authority
MA
Morocco
Prior art keywords
symptoms
treatment
methods
protection against
associated conditions
Prior art date
Application number
MA050582A
Other languages
English (en)
Inventor
Jr Richard Thomas George
Chao-Yu Jin
Original Assignee
Alphacore Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphacore Pharma Llc filed Critical Alphacore Pharma Llc
Publication of MA50582A publication Critical patent/MA50582A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01043—Phosphatidylcholine-sterol O-acyltransferase (2.3.1.43), i.e. lecithin-cholesterol acyltransferase or LCAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
MA050582A 2017-11-07 2018-11-05 Méthodes de traitement et de protection contre une maladie cardiaque, une maladie cardiovasculaire et des états et des symptômes associés MA50582A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762582382P 2017-11-07 2017-11-07
US201862629900P 2018-02-13 2018-02-13

Publications (1)

Publication Number Publication Date
MA50582A true MA50582A (fr) 2020-09-16

Family

ID=66438309

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050582A MA50582A (fr) 2017-11-07 2018-11-05 Méthodes de traitement et de protection contre une maladie cardiaque, une maladie cardiovasculaire et des états et des symptômes associés

Country Status (12)

Country Link
US (1) US20200261549A1 (fr)
EP (1) EP3706781A4 (fr)
JP (1) JP2021501793A (fr)
KR (1) KR20200085292A (fr)
CN (1) CN111601614A (fr)
AU (1) AU2018362603A1 (fr)
CA (1) CA3082070A1 (fr)
IL (1) IL274360A (fr)
MA (1) MA50582A (fr)
SG (1) SG11202003835PA (fr)
TW (1) TW201929894A (fr)
WO (1) WO2019092584A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114999674B (zh) * 2022-05-27 2024-07-02 中国药科大学 Qsp-pbpk-td模型构建方法及药源性心功能损伤预测方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2283007T3 (es) * 1995-11-09 2007-10-16 The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services Utilizacion de la lecitina colesterol aciltransferasa (lcat) en el tratamiento de la aterosclerosis.
WO2006069371A1 (fr) * 2004-12-22 2006-06-29 Baylor College Of Medicine Methode de lipidation plasmatique destinee a prevenir, a inhiber et/ou a inverser l'atherosclerose
EP2489731B1 (fr) * 2007-07-26 2014-08-27 Amgen, Inc Enzymes de cholestérol lécithine-acyltransférase modifiées
EP2020603A1 (fr) * 2007-08-03 2009-02-04 BRAHMS Aktiengesellschaft Procédé de stratification du risque chez des patients ayant une maladie associeé avec des coronaropathies
US8999932B2 (en) * 2009-07-29 2015-04-07 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
WO2011140429A1 (fr) * 2010-05-06 2011-11-10 Alphacore Pharma Llc Administration d'ester de cholestéryle à des tissus stéroïdogènes
CN103118683B (zh) * 2010-06-30 2015-08-19 杰特有限公司 重建高密度脂蛋白制剂及其生产方法
JP6635655B2 (ja) * 2011-12-08 2020-01-29 アムジエン・インコーポレーテツド ヒトｌｃａｔ抗原結合タンパク質および治療法におけるそれらの使用
RU2675824C2 (ru) * 2013-09-11 2018-12-25 Игл Байолоджикс, Инк. Жидкие белковые составы, содержащие ионные жидкости
EP3215180A4 (fr) * 2014-11-04 2018-07-11 Rappaport Family Institute for Research in the Medical Sciences Méthodes et kits de traitement de maladies cardiovasculaires

Also Published As

Publication number Publication date
US20200261549A1 (en) 2020-08-20
KR20200085292A (ko) 2020-07-14
AU2018362603A1 (en) 2020-06-18
WO2019092584A1 (fr) 2019-05-16
SG11202003835PA (en) 2020-05-28
CN111601614A (zh) 2020-08-28
JP2021501793A (ja) 2021-01-21
EP3706781A1 (fr) 2020-09-16
IL274360A (en) 2020-06-30
CA3082070A1 (fr) 2019-05-16
EP3706781A4 (fr) 2021-07-21
TW201929894A (zh) 2019-08-01

Similar Documents

Publication Publication Date Title
IL284423B (en) Antisense oligonucleotides for the treatment of Pompe disease
MA43374A (fr) Méthodes de traitement de tumeurs malignes
DK3789501T3 (da) Fremgangsmåde til diagnosticering, behandling og forebyggelse af parkinsons sygdom
HK1259031A1 (zh) 使用治療有效量的活化脂肪酸預防、治療和逆轉疾病
MA48730A (fr) Compositions et méthodes de traitement de synucléinopathies
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
MA42287A (fr) Traitement de patients atteints de diabète sucré de type 2
EA201692202A1 (ru) Способы лечения сердечно-сосудистых заболеваний
MA43755A (fr) Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte
MA50582A (fr) Méthodes de traitement et de protection contre une maladie cardiaque, une maladie cardiovasculaire et des états et des symptômes associés
MA41782A (fr) Traitement de patients atteints de diabète de type 2
MA50914A (fr) Vecteurs viraux comprenant des séquences codantes de rdh12 et méthodes de traitement de dystrophies rétiniennes
GB201515244D0 (en) Treatment of inflammatory disease or condition
PL3137097T3 (pl) Leczenie i profilaktyka choroby Alzheimera (AD)
PH12020550589A1 (en) Improved compound for treatment of heart failure
LT3137093T (lt) Alzheimerio ligos (ad) gydymas ir prevencija
PL3137094T3 (pl) Leczenie i profilaktyka choroby alzheimera (ad)
MA49754A (fr) Méthodes de traitement de symptômes de gastroparésie au moyen de velusetrag
MA48477A (fr) Compositions et méthodes de traitement de la dépression
HK1245146A1 (zh) 尿酸性或痛風性疾病的預防或治療
FR3016881B1 (fr) Traitement des degenerescences et des lesions photo-induites de la retine
MA45177A (fr) Traitement de la maladie de parkinson
MA49358A (fr) Compositions et méthodes de traitement de tauopathies
IL263837A (en) Treatment of ocular disease
GB201610906D0 (en) Treatment of cardiovascular disease